What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

1. Efficacy and safety of [Frontiers in medicine · 2026
   Pooled it
2. Organ and tumor dosimetry of [European journal of nuclear medicine and molecular imaging · 2026
   Article
3. Outcome and Safety of Radioligand Therapy With [ 161 Tb]Tb-PSMA-617 After Re-Progression in mCRPC Patients Previously Treated With [ 177 Lu]Lu-PSMA-617.Clinical nuclear medicine · 2026
   Observational
4. QuantitativeEJNMMI physics · 2026
   Article
5. Advances in the Rational Design, Mechanisms, and Applications of Lanthanide Nanoparticles for the Regulation of Reactive Oxygen Species.International journal of nanomedicine · 2026
   Review
6. Challenges and Opportunities in Radioligand Therapy.Journal of nuclear medicine technology · 2025
   Review
7. The Role of Nuclear Medicine in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025
   Review
8. Recommendations for Standardizing Nuclear Medicine Terminology and Data in the Era of Theranostics and Artificial Intelligence.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
   Article
9. Radionuclides Landscape in Prostate Cancer Theranostics.International journal of molecular sciences · 2025
   Review
10. The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer.European journal of nuclear medicine and molecular imaging · 2025
    Review
11. Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.Nuclear medicine and molecular imaging · 2025
    Review
12. Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025
    Review
13. How to Harness the Power of GPT for Scientific Research: A Comprehensive Review of Methodologies, Applications, and Ethical Considerations.Nuclear medicine and molecular imaging · 2024
    Review
14. Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer.Cancers · 2024
    Review
15. Separation of terbium as a first step towards high purity terbium-161 for medical applications.RSC advances · 2024
    Article
16. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.The Lancet. Oncology · 2024
    Review
17. From Despair to Hope: First Arabic Experience ofCancers · 2024
    Article
18. Combination of [European journal of nuclear medicine and molecular imaging · 2024
    Article
19. Intense prostate-specific membrane antigen receptor expression in coronary artery pypass graft scar tissue: A potential molecular imaging pitfall.Acta radiologica open · 2024
    Article
20. [Theranostics · 2024
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as